Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics

Molecular Pharmacology

Volumn 65, Issue 5, 2004, Pages 1278-1285

  Chen, Chong Sheng ^a   Lin, Jack T ^a   Goss, Kendrick A ^a   He, You Ai ^b   Halpert, James R ^b   Waxman, David J ^a  

^a Boston University   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B; CYTOCHROME P450 2B1; IFOSFAMIDE; MUTANT PROTEIN; OXAZAPHOSPHORINE; OXYGENASE;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DOG; DRUG ACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME SUBSTRATE; ESCHERICHIA COLI; EXPERIMENTAL RAT; GENE EXPRESSION SYSTEM; HUMAN; HYDROXYLATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RABBIT; RAT; SUBSTITUTION REACTION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; IFOSFAMIDE; KINETICS; MUTATION; PRODRUGS; RATS; STEROID HYDROXYLASES;

EID: 2142823779     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.5.1278     Document Type: Article

References (42)

1. Bohnenstengel F, Eichelbaum M, Golbs E, and Kroemer HK (1997) High-performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes. J Chromatogr B Biomed Sci Appl 692:163-168.
2. Borner K, Kisro J, Bruggemann SK, Hagenah W, Peters SO, and Wagner T (2000) Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drug Metab Dispos 28:573-576.
3. Chang TK, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
4. Chang TK, Yu L, Goldstein JA, and Waxman DJ (1997) Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7:211-221.
5. Chen L and Waxman DJ (2002) Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 8:1405-1416.
6. Chun R, Garrett LD, and Vail DM (2000) Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 14:120-124.
7. Clarke L and Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49:2344-2350.
8. Domanski TL and Halpert JR (2001) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117-137.
9. Domanski TL, Schultz KM, Roussel F, Stevens JC, and Halpert JR (1999) Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis and molecular modeling. J Pharmacol Exp Ther 290:1141-1147.
10. Dorr RT and Von Hoff DD (1994) Cancer Chemotherapy Handbook, p. 322, Appleton & Lange, Norwalk, Connecticut.
11. Duignan DB, Sipes IG, Leonard TB, and Halpert JR (1987) Purification and characterization of the dog hepatic cytochrome P-450 isozyme responsible for the metabolism of 2,2′,4,4′,5,5′-hexachlorobiphenyl. Arch Biochem Biophys 255:290-303.
12. Furlanut M and Franceschi L (2003) Pharmacology of ifosfamide. Oncology 65 (Suppl 2):2-6.
13. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
14. Granvil CP, Madan A, Sharkawi M, Parkinson A, and Wainer IW (1999) Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 27:533-541.
15. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402.
16. Harlow GR, He YA, and Halpert JR (1997) Functional interaction between amino-acid residues 242 and 290 in cytochromes P-450 2B1 and 2B11. Biochim Biophys Acta 1338:259-266.
17. Hasler JA, Harlow GR, Szklarz GD, John GH, Kedzie KM, Burnett VL, He YA, Kaminsky LS, and Halpert JR (1994) Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290, and 363 for substrate specificity. Mol Pharmacol 46:338-345.
18. He YQ, He YA, and Halpert JR (1995) Escherichia coli expression of site-directed mutants of cytochrome P450 2B1 from six substrate recognition sites: substrate specificity and inhibitor selectivity studies. Chem Res Toxicol 8:574-579.
19. He YQ, Szklarz GD, and Halpert JR (1996) Interconversion of the androstenedione hydroxylase specificities of cytochromes P450 2B4 and 2B5 upon simultaneous site-directed mutagenesis of four key substrate recognition residues. Arch Biochem Biophys 335:152-160.
20. Huang Z, Roy P, and Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961-972.
21. Huang Z and Waxman DJ (1999) High-performance liquid chromatographic- fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations. Anal Biochem 273:117-125.
22. Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM, and Chiocca EA (2001) Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res 61:864-868.
23. John GH, Hasler JA, He YA, and Halpert JR (1994) Escherichia coli expression and characterization of cytochromes P450 2B11, 2B1, and 2B5. Arch Biochem Biophys 314:367-375.
24. Jounaidi Y, Hecht JED, and Waxman DJ (1998) Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 58:4391-4401.
25. Jounaidi Y and Waxman DJ (2004) Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 64:292-303.
26. Kan O, Griffiths L, Baban D, Iqball S, Uden M, Spearman H, Slingsby J, Price T, Esapa M, Kingsman S, et al. (2001) Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther 8:473-482.
27. Kumar S, Scott EE, Liu H, and Halpert JR (2003) A rational approach to re-engineer cytochrome P450 2B1 regioselectivity based on the crystal structure of cytochrome P450 2C5. J Biol Chem 278:17178-17184.
28. Lewis DF and Lake BG (1997) Molecular modelling of mammalian CYP2B isoforms and their interaction with substrates, inhibitors and redox partners. Xenobiotica 27:443-478.
29. Li QS, Schwaneberg U, Fischer M, Schmitt J, Pleiss J, Lutz-Wahl S, and Schmid RD (2001) Rational evolution of a medium chain-specific cytochrome P-450 BM-3 variant. Biochim Biophys Acta 1545:114-121.
30. Lohr M, Hoffmeyer A, Kroger J, Freund M, Hain J, Holle A, Karle P, Knofel WT, Liebe S, Muller P, et al. (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357:1591-1592.
31. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, and Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735.
32. Roy P, Tretyakov O, Wright J, and Waxman DJ (1999) Stereoselective metabolism of ifosfamide by human P450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 27:1309-1318.
33. Scott EE, He YA, Wester MR, White MA, Chin CC, Halpert JR, Johnson EF, and Stout CD (2003) An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution. Proc Natl Acad Sci USA 100:13196-13201.
34. Shimada T and Yamazaki H (1998) Cytochrome P450 reconstitution systems. Methods Mol Biol 107:85-93.
35. Sladek NE (1994) Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines, in Anticancer Drugs: Reactive Metabolism and Interactions (Powers G ed) pp 79-156, Pergamon Press, Oxford, England.
36. Strobel SM and Halpert JR (1997) Reassessment of cytochrome P450 2B2: catalytic specificity and identification of four active site residues. Biochemistry 36:11697-11706.
37. Szklarz GD and Halpert JR (1997) Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 61:2507-2520.
38. Szklarz GD, He YQ, Kedzie KM, Halpert JR, and Burnett VL (1996) Elucidation of amino acid residues critical for unique activities of rabbit cytochrome P450 2B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome P450 2B4. Arch Biochem Biophys 327:308-318.
39. Walsh ME, Kyritsis P, Eady NA, Hill HA, and Wong LL (2000) Catalytic reductive dehalogenation of hexachloroethane by molecular variants of cytochrome P450cam (CYP101). Eur J Biochem 267:5815-5820.
40. Weber GF and Waxman DJ (1993) Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem Pharmacol 45:1685-1694.
41. Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D, and Stout CD (2003) Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. Biochemistry 42: 6370-6379.
42. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, and Jhoti H (2003) Crystal structure of human cytochrome P460 2C9 with bound warfarin. Nature (Lond) 424:464-468.